TY - JOUR
T1 - Multiparametric MRI for prostate cancer diagnosis
T2 - current status and future directions
AU - Stabile, Armando
AU - Giganti, Francesco
AU - Rosenkrantz, Andrew B.
AU - Taneja, Samir S.
AU - Villeirs, Geert
AU - Gill, Inderbir S.
AU - Allen, Clare
AU - Emberton, Mark
AU - Moore, Caroline M.
AU - Kasivisvanathan, Veeru
N1 - Publisher Copyright:
© 2019, Springer Nature Limited.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - The current diagnostic pathway for prostate cancer has resulted in overdiagnosis and consequent overtreatment as well as underdiagnosis and missed diagnoses in many men. Multiparametric MRI (mpMRI) of the prostate has been identified as a test that could mitigate these diagnostic errors. The performance of mpMRI can vary depending on the population being studied, the execution of the MRI itself, the experience of the radiologist, whether additional biomarkers are considered and whether mpMRI-targeted biopsy is carried out alone or in addition to systematic biopsy. A number of challenges to implementation remain, such as ensuring high-quality execution and reporting of mpMRI and ensuring that this diagnostic pathway is cost-effective. Nevertheless, emerging clinical trial data support the adoption of this technology as part of the standard of care for the diagnosis of prostate cancer.
AB - The current diagnostic pathway for prostate cancer has resulted in overdiagnosis and consequent overtreatment as well as underdiagnosis and missed diagnoses in many men. Multiparametric MRI (mpMRI) of the prostate has been identified as a test that could mitigate these diagnostic errors. The performance of mpMRI can vary depending on the population being studied, the execution of the MRI itself, the experience of the radiologist, whether additional biomarkers are considered and whether mpMRI-targeted biopsy is carried out alone or in addition to systematic biopsy. A number of challenges to implementation remain, such as ensuring high-quality execution and reporting of mpMRI and ensuring that this diagnostic pathway is cost-effective. Nevertheless, emerging clinical trial data support the adoption of this technology as part of the standard of care for the diagnosis of prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=85069436989&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069436989&partnerID=8YFLogxK
U2 - 10.1038/s41585-019-0212-4
DO - 10.1038/s41585-019-0212-4
M3 - Review article
C2 - 31316185
AN - SCOPUS:85069436989
SN - 1759-4812
VL - 17
SP - 41
EP - 61
JO - Nature Reviews Urology
JF - Nature Reviews Urology
IS - 1
ER -